Archive for October, 2013

Genetics - After The Ordeal @ Teatro Coliseo, Bs As, 21/09/13.
Genetics - After The Ordeal (Selling England by the Pound, 1973). Teatro Coliseo, Bs As, Argentina. Sábado 21 de Septiembre de 2013. HD Stereo.

By: Gino Zolezzi

See the rest here:
Genetics - After The Ordeal @ Teatro Coliseo, Bs As, 21/09/13. - Video

The Genetics of Multiple Sclerosis
The Genetics of Multiple Sclerosis.

By: msworldinc

Continued here:
The Genetics of Multiple Sclerosis - Video

Dr Pillai (Baba) Reveals His Avatar Part 2 of 3: Soul Genetics - Tarpanam For Your Ancestors
http://www.pillaicenter.com/ Free MP3: http://www.pillaicenter.com/LiveHangout.aspx Subscribe http://www.youtube.com/subscription_center?add_user?=PillaiCent...

By: PillaiCenter

See the original post here:
Dr Pillai (Baba) Reveals His Avatar Part 2 of 3: Soul Genetics - Tarpanam For Your Ancestors - Video

Technology Transfer At VGTI Florida®
Technology Transfer at VGTI Florida® encompasses the process of identification of new discoveries that rise to the level of invention, protection of the resu...

By: VGTI Florida

Read more:
Technology Transfer At VGTI Florida® - Video

About VGTI Florida®
The Vaccine and Gene Therapy Institute of Florida is an independent non-profit research institution dedicated to the study of the human immune system. VGTI Florida® #39;s mission is "Translating...

By: VGTI Florida

Follow this link:
About VGTI Florida® - Video

Freeport, The Bahamas (PRWEB) October 03, 2013

Okyanos Heart Institute, whose mission is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, has announced that they will be hosting a free educational seminar for the business community and all other interested individuals on Tuesday, October 22nd from 5:30 6:30 pm in the Coral Reef Room of the Pelican Bay Hotel in Lucaya, Grand Bahama Island. Registration is requested to attend as seating is limited.

Howard Walpole, M.D., M.B.A., F.A.C.C., F.S.C.A.I. and chief medical officer and interventional cardiologist for Okyanos Heart Institute will provide an overview of stem cell therapy for heart disease, the source of stem cells, how it is intended to work, and the protocol that will be used by the cath lab for patients once the facility is open in February, 2014. Erika Mangrum, SVP of Communications for the company, will provide an overview of what services will be needed by small businesses on the island, such as janitorial, hospital grade laundry, transportation, catering and more. A preliminary list of jobs that Okyanos Heart Institute will need to fill towards the end of the year will also be shared.

We welcome the local business community to learn about what we will be doing in treating patients with heart disease, said Walpole. Stem cell therapy is a growing field still with some confusion around where stem cells come from, what they do, and how they can potentially help someone with heart disease. We want to answer as many questions as we can.

President of The Grand Bahama Port Authority, Limited (GBPA) Ian Rolle, is pleased with how plans are progressing as the Institute prepares to open its doors locally in early 2014. Legislation has recently been enacted to support stem cell therapy, research and development in The Bahamas. This is of monumental proportions as Grand Bahama Island is now poised to become a leading centre for medical advancement, Rolle said. We heartily welcome the Okyanos Heart Institute and support their efforts towards public education. Additionally, the employment of skilled professionals and outsourcing of ancillary services, mean permanent engagement and greater business opportunities for many of our citizenry.

Okyanos Heart Institute will have a number of service needs from the local business community, said Mangrum. We hope to meet potential suppliers and servicers and share what our needs will be from service providers, and share employment needs once we are close to opening in February. We could not be more enthused about bringing patients to the beautiful island of Grand Bahama in the hopes of improving the quality of their lives by restoring flow to their hearts.

Registration for the seminar is requested as seating is limited. Call 242-688-2667 or email freeseminar(at)okyanos(dot)com by Oct 18.

ABOUT OKYANOS HEART INSTITUTE: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. The treatment facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos (Oceanos) symbolizes flow. For more information, go to http://www.okyanos.com.

The rest is here:
Okyanos Heart Institute Offers Educational Seminar About Cardiac Stem Cell Therapy In Lucaya, Grand Bahama

Mayo Clinic Researchers Apply Regenerative Medicine to Battlefield Injuries
Mayo Clinic researchers are part of the second phase of a national consortium that focuses on developing innovative medical treatments for wounded veterans. ...

By: Mayo Clinic

More here:
Mayo Clinic Researchers Apply Regenerative Medicine to Battlefield Injuries - Video

Pioneering Regenerative Medicine, Dr. Anthony Atala - Andy Anderson - GE FOCUS FORWARD
Subscribe to the GE Channel: http://full.sc/12xcByI Dr. Anthony Atala pioneered the field of regenerative medicine as the first to successfully engineer, gro...

By: General Electric

More:
Pioneering Regenerative Medicine, Dr. Anthony Atala - Andy Anderson - GE FOCUS FORWARD - Video

Oct. 3, 2013 When developing new drugs, monitoring cellular responses to candidate compounds is essential for assessing their efficacy and safety. Researchers from the RIKEN Center for Life Science Technologies report a new method to monitor and quantify the activity of gene promoters during the response to a drug, using the advanced gene expression analysis method CAGE followed by single-molecule sequencing. This research paves the way to a more precise analysis of cellular responses to drugs, at the level of individual promoters.

The study is published this week in the journal CPT: Pharmacometrics & Systems Pharmacology.

Microarray-based technologies are widely used to monitor cellular changes in response to drug administration at the level of genes. However, microarrays have several limitations due to the fact that they rely on pre-designed oligonucleotide probes and detection based on hybridization.

In order to circumvent the limitations imposed by the use of microarray-based technology for the development of new drugs, Dr Harukazu Suzuki and his team at CLST developed a new technique combining Cap Analysis of Gene Expression (CAGE) with 3rd generation, single-molecule sequencing. CAGE is a method developed at RIKEN to comprehensively map human transcription start sites and their promoters, and quantify the set of mRNAs in a cell, also called the transcriptome.

During CAGE the 5'-end of mRNAs is sequenced in order to produce a series of 20-30 nucleotide sequences that can then be mapped onto the genome and provide information about the level of expression of genes. Dr Suzuki and his team used CAGE, combined with a single-molecule sequencer, to monitor the effect of three drugs, U0126, wortmannin and gefitinib on human breast cancer cells.

U0126 and wortmannin are known to inhibit the Ras-ERK and phosphatidylinositol-3-kinase (PI3K)-Akt signalling pathways within cells. Gefinitib is a potent inhibitor of the epidermal growth factor receptor kinase (EGFR kinase) and mainly inhibits the Ras-ERK and PI3K-Akt pathways downstream of EGFR.

The researchers identified a distinct set of promoters that were affected by low doses of the drugs, and therefore showed sensitivity to a weak inhibition of the Ras-ERK and PI3K-Akt signal-transduction pathways. This level of precision would would have been very difficult to achieve using microarray-based profiling.

Furthermore, a quantitative analysis showed that the inhibitory profiles of both U0126 and wortmannin are constitutive components of the transcriptome profile obtained by inhibition of the EGFR kinase. Using a regression model, the researchers were able to quantitatively predict the promoter activity profile of gefitinib, based on the U0126 and wortmannin profiles.

These results demonstrate the potential utility of highly quantitative promoter activity profiling in drug research.

"Quantitative transcriptome analysis is potentially widely applicable to determine the target proteins and action mechanisms of uncharacterized compounds," concludes Dr Suzuki. "Our study paves the way for quantitative analysis of drug responses at the promoter level, and moreover, is potentially applicable for the evaluation of combinatorial or serial drug treatment in a clinical setting," he adds.

See the original post here:
Advanced technology for gene expression analysis can facilitate drug development

PHILADELPHIA This Sunday, the lifesaving efforts of the University of Pennsylvanias Basser Research Center for BRCA will take root in Congregation Rodeph Shalom at a special event to raise awareness about hereditary breast and ovarian cancers within the Jewish community. The panel discussion, which will gather medical experts and genetic counselors alongside clergy, cancer advocates, survivors and previvors, aims to call attention to a striking statistic: 1 in 40 individuals of Ashkenazi Jewish ancestry who comprise 90 percent of Jews living in the U.S. carries a BRCA mutation, more than ten times the risk of the general population. Men can carry and pass on the gene mutations, too.

Experts will share the latest news on genetic testing for these mutations, which greatly increase carriers lifetime risk of developing breast and ovarian cancers and are also linked to prostate, pancreatic and colon cancers. CBS3/CW Philly 57 Medical Reporter Stephanie Stahl will emcee the event, which will include an opportunity for the audience to ask questions of the panel and for individuals to meet one-on-one with genetic counselors from Penn Medicine.

This event is the first of a three-part educational series co-hosted by Penn Medicines Basser Research Center for BRCA and Living Beyond Breast Cancer, a national nonprofit organization that provides educational resources and support to women affected by breast cancer, their families and caregivers. This partnership, made possible by a grant from Women of Vision, the Jewish Womens Foundation of Greater Philadelphia, also brings together breast and ovarian cancer advocates from FORCE: Facing Our Risk of Cancer Empowered, Sharsheret and Bright Pink.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and theUniversity of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals byU.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided$827million to benefit our community.

Read the original:
To Save A Life: Penn Medicine's Basser Research Center for BRCA Brings Hereditary Cancer Awareness Mission Into ...

San Jose, California (PRWEB) October 04, 2013

Follow us on LinkedIn Predictive diagnostics refer to a series of genetic tests that determine individual susceptibility to diseases, individual response to specific therapies/interventions and the outcome of diseases. Genetic testing has emerged as a lucrative sector in the molecular diagnostics market led by the fact that appropriate and accurate diagnosis is the cornerstone of advanced healthcare. Predictive testing involves identifying the presence or inheritance of faulty gene among members of a family, such as those resulting in Tay-Sachs disease, cystic fibrosis, Lou Gehrig's disease, Huntington's disease and Alzheimer's disease. Predictive diagnostics are also beneficial in examining the gene composition and interaction in diseased tissue/cells to understand and determine progress of the disease as well as the response to treatment.

Though a relatively small market, predictive diagnostics is witnessing steady growth owing to increasing awareness among medical professionals and patients. Proportional to rising life expectancy and mean age, chronic degenerative diseases (CDD) including cardiovascular diseases, neurodegenerative disorders, cancer and autoimmune diseases, have surged globally, translating into demand for predictive testing. The rapidly ageing society in major Western and Eastern economies is therefore a prime driver of demand for predictive diagnostics for age-related disorders. Traditionally offered through physicians, genetic testing kits are now being offered directly to the consumer through web-based stores. However, the security and utility of DTC genetic testing kits is being questioned as several companies tend to circumvent third party reimbursement and regulatory issues.

Decreasing costs coupled with the enhanced efficiency and speed of gene sequencing has resulted in rapidly unfurling information on cancer gene mechanisms. With the cost of sequencing the entire genome falling below US$1,000 in comparison to anti-cancer treatments which cost over US$50,000, physicians are opting to conduct genomic tests to determine patient drug response, following which medications are prescribed to only those patients who are more likely to respond to a specific cancer therapy or treatment option. Technological advancements in genomics such as Next-Generation Sequencing (NGS) are replacing conventional DNA sequencing modalities. Advanced NGS systems offer the capability of sequencing and comparing up to 4 human genomes within a space of two weeks. Demand for genetic tests designed for screening newborn infants, diagnosis of orphan diseases and other rare or fatal disorders, and assessment of the probability of occurrence of conditions such as Huntingtons disease, is expected to expand dramatically in the near term. On the flip side, as the new era of genetic medicine dawns upon the healthcare sector, the need of the hour is a clear and comprehensive framework addressing the medical, economic, ethical and legal aspects of subjecting healthy individuals to genetic testing for disease prevention.

As stated by the new market research report on Predictive Diagnostics, the United States represents the largest market worldwide. Screening for genetic mutations within the CFTR (cystic fibrosis trans-membrane conductance regulator) gene is the most frequently conducted test in the country. While developed economies with advanced healthcare infrastructure are at the forefront in the adoption of predictive genetic testing, population growth and recent government initiatives to improve healthcare delivery to all sections of the population is expected to propel demand in developing countries in the near future. Countries such as China harbor the largest prospects for breast cancer gene testing. Attributed to lifestyle changes as a result of rapid industrialization and increasing urbanization, the country is registering a surge in cases of breast cancer.

Major players covered in the report include Abbott Molecular, Almac Group Ltd., BioGenex, Covance Inc., Dako Denmark A/S, Epistem Plc, F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH Inc., Myriad Genetics Inc., Precision Therapeutics Inc., Prometheus Laboratories, QIAGEN N.V., among others.

The research report titled "Predictive Diagnostics: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, drivers, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections for major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, and Rest of Europe), and Rest of World.

For more details about this comprehensive market research report, please visit http://www.strategyr.com/Predictive_Diagnostics_Market_Report.asp

About Global Industry Analysts, Inc. Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Excerpt from:
Advances in Genetic Sequencing to Augment Growth in the Predictive Diagnostics Market, According to New Report by ...

Genetics part 1 introduction to advanced genetics
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Mende...

By: Suman Bhattacharjee

The rest is here:
Genetics part 1 introduction to advanced genetics - Video

Genetics part 4 polygenic inheritance
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Quant...

By: Suman Bhattacharjee

Continued here:
Genetics part 4 polygenic inheritance - Video

Genetics problems 10 polygenic inheritance
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Genet...

By: Suman Bhattacharjee

Go here to see the original:
Genetics problems 10 polygenic inheritance - Video

Genetics problems 13 blood group problems
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Genet...

By: Suman Bhattacharjee

Excerpt from:
Genetics problems 13 blood group problems - Video

kush dreams dna genetics
kush dreams dna genetics.

By: jm9300

The rest is here:
kush dreams dna genetics - Video

13 - Genetics

By: A P

Read more:
13 - Genetics - Video

Controversy is brewing after a genetics company received a patent that might allow prospective parents to calculate the traits of their future offspring.

23AndMe is a company that allows the average consumer to analyze their genetic code. The test provides genetic information on more than 240 disease and physical traits, which can be used for various reasons including determining personal risk of getting breast cancer or helping long-lost siblings find each other.

Play Video

"We started the company really with the idea that we wanted to do something revolutionary, where consumers could come, learn tons of information about themselves and really start to revolutionize health care," 23andMe co-founder Anne Wojcicki previously told CBS This Morning in July 2012.

The U.S. company recently received a patent for their Family Traits Inheritor Calculator, which allows couples to send in a saliva sample to see what kinds of genetic traits and diseases could be passed to their children.

However, the application for the patent stated that the company was also seeking to use this technology in fertility clinics. This led critics to think that couples could potentially create "designer babies," not only picking children based on disease avoidance but on their looks and other physical characteristics. Especially in the fertility clinic setting, the "GATTICA"-like scenario would allow couples to screen through numerous egg and sperm donors in order to pick a genetically superior child.

"It would be highly irresponsible for 23andMe or anyone else to offer a product or service based on this patent," Marcy Darnovsky, executive director of the Center for Genetics and Society, said in a statement.

"We believe the patent office made a serious mistake in allowing a patent that includes drop-down menus for which to choose a future child's traits," she added.

A commentary in Genetics and Medicine published on Oct. 3 also warned against parents using the technology to hand-pick genes for their children. The authors called the practice "ethically controversial."

"The use of preimplantation genetic diagnosis to avoid implantation of embryos bearing serious genetic abnormalities is by now becoming commonplace, but a computerized process for selecting gamete donors to achieve a baby with a 'phenotype of interest' that the prospective parent 'desires in his/her hypothetical offspring,' as 23andMe puts it, seems to have much broader implications, for this process also entails the selection of traits that are not disease related," they wrote.

The rest is here:
Critics fear new patent will breed "designer babies"

RUTHERFORD, N.J., Oct. 4, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, today announced its president and CEO, Panna Sharma, will participate in a panel discussion at BioNJ's inaugural CEO Summit from 1:40 p.m. to 2:40 p.m. ET on October 4, 2013 in Bridgewater, New Jersey. The first of its kind summit will bring together chief executive officers and leaders from major biotech and pharmaceutical firms from New Jersey and beyond this fall to share their knowledge, experiences and views on the future in wide-ranging discussions with fellow executives, investors, entrepreneurs, academics and other members of the State's diverse and ever-evolving life sciences community.

The panel discussion, "How Wide is the Crack in the IPO Window," will feature first-hand IPO experiences shared by Mr. Sharma and other panelists from biotech companies such as Chimerix and Omthera Pharmaceuticals that all went public during 2013. In April of 2013, Mr. Sharma successfully led CGI through an IPO and secondary offering in August, raising gross proceeds in excess of $23 million for the Company. CGI is ranked the 8th best biotech IPO of the year and one of the top-20 overall best-performing IPOs for 2013, based on year-to-date returns through the close of trading on October 1, 2013.

Mr. Sharma became a board member and CEO of CGI in May of 2010. Under his tenure, CGI has consistently grown revenues and margins while launching five proprietary DNA-based cancer diagnostics and establishing partnerships and collaborations with leading cancer institutions, including Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and National Cancer Institute. Mr. Sharma also serves on the board of CGI's joint venture in next-generation sequencing with the Mayo Clinic, Oncospire Genomics, based in Rochester, Minnesota.

Prior to CGI, Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010, where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy- and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry.

Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. ("iXL"), a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999.

The BioNJ CEO Summit will take place at the Bridgewater Marriott in Bridgewater, New Jersey. To register, please visit http://www.bionj.org/

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Read the original post:
Cancer Genetics, Inc. CEO Panna Sharma to Participate in Panel at BioNJ CEO Summit

SEATTLE, WA--(Marketwired - Oct 4, 2013) - Atossa Genetics Inc. (NASDAQ: ATOS), The Breast Health Company, will host a conference call at 5:45 pm Eastern Time today to discuss the Company's voluntary recall of its ForeCYTE Breast Health Test; Mammary Aspiration Specimen Cytology Test (MASCT) System, which was announced today at 5:00 pm Eastern Time.

To listen to the call by phone, interested parties within the U.S. may dial 866-652-5200. International callers should dial 412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at http://services.choruscall.com/links/atossa131003.html.

A replay of the call will be available one hour after the end of the call through November 4, 2013, and can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID number is 10034877.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on the commercialization of patented, diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests designed to assess breast health.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit http://www.atossagenetics.com and http://www.nrlbh.com.

View post:
Atossa Genetics Conference Call and Webcast Notice

Genetics and Gene Therapy Concerning Hormones
Gene Therapy and Genetics program by the Conscious Evolution Institute of Hormone Replacement Therapy. For more information visit the Conscious Evolution Ins...

By: HGH Testosterone Sermorelin HCG

Read more:
Genetics and Gene Therapy Concerning Hormones - Video

Mice with and without gene therapy treatment
These mice are male "Rett" mice. The mouse moving around was given gene therapy treatment and received healthy Mecp2 gene. The immobile mouse did not receive...

By: reverserett

Continue reading here:
Mice with and without gene therapy treatment - Video

Cecilia Lundberg, Professor of Neuroscience, Lund University
Cecilia Lundberg #39;s research group is focused on developing vectors for use in gene therapy to treat diseases in the brain. Furthermore, they also aim to expl...

By: LundUniversity

See the original post:
Cecilia Lundberg, Professor of Neuroscience, Lund University - Video

Nicolas Chomont, Ph.D. - Principal Investigator
Nicolas Chomont, Ph.D.Nicolas Chomont, Ph.D., is a principal investigator at the Vaccine Gene Therapy Institute of Florida. He is an internationally recogn...

By: VGTI Florida

Go here to read the rest:
Nicolas Chomont, Ph.D. - Principal Investigator - Video

AMSTERDAM, Netherlands, Oct. 4, 2013 (GLOBE NEWSWIRE) -- uniQure B.V., a leader in human gene therapy, today announced that Christian Meyer, M.D., Ph.D., has joined the company as Chief Medical Officer. Dr. Meyer has 18 years of clinical research experience with both biotechnology companies and large pharma, with particular expertise in the development of treatments for rare diseases, including Acute Intermittent Porphyria and lysosomal storage disorders.

"Since joining uniQure early in the year as a consultant, Christian has built an extremely experienced clinical development team. This team is operating already at a high level as our pipeline programs advance into further clinical evaluation in the next 12-24 months," said Jorn Aldag, CEO of uniQure. "Christian's leadership in clinical development as well as his focus on rare diseases is a tremendous resource for the company and we are very glad to welcome him officially to the management team."

"I have been impressed with both the company's achievements in gaining approval for Glybera in the European Union and the potential of our gene therapy approach," added Dr. Meyer. "I am fully committed to reaching the next level of development for our pipeline."

Christian Meyer joins uniQure from Cardoz AB where he spent three years as Chief Medical Officer. From 2006 to 2010, Dr. Meyer held leadership positions in clinical development at Symphogen A/S, where he was Senior Vice President for Medical Affairs and Vice President, Clinical Development. Prior to Symphogen, he played an important role in clinical development at Zymenex A/S and spent five years in clinical development at Novo Nordisk A/S. Dr. Meyer received both his M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.

About uniQure

uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera. http://www.uniqure.com.

Press release (PDF): http://hugin.info/157414/R/1733550/580459.pdf

Read more from the original source:
Christian Meyer Joins uniQure as Chief Medical Officer